Tekmira said Wednesday it was looking into ways its Ebola drug, which hasn’t been formally cleared by regulators, can be used to fight the outbreak in West Africa. The company also reported a second-quarter net loss of $6.1 million, or 28 cents a share, on revenue that fell to $1.8 million from $2.8 million a year earlier.
Shares of Tekmira rose 0.9% to $16.64 on Friday morning. Shares have jumped 30% in August and more than doubled this year.
Shares of Tekmira listed on Toronto Stock Exchange rose 10.5% to close at $19.73